YM BioSciences provides update on AeroLEF(TM) clinical developme... ( MISSISSAUGA ON Jan. 17 / YM BioSc...)

YM BioSciences provides update on AeroLEF(TM) clinical development program

Date:1/17/2008

MISSISSAUGA, ON, Jan. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that it has received a letter from the U.S. Food and Drug Administration (FDA) informing the Company that the Phase II Acute Pain Study (AP5) of AeroLEF(TM) for which FDA clearance was announced on June 27, 2007, upon re-review of data from the IND submission, has been placed on clinical hold. The FDA has requested additional safety information on specific patients in previous clinical studies. The additional requested data is limited to a small group of patients that experienced oxygen desaturation, a class effect of opioids including fentanyl. The Company will conduct a subgroup analysis on these patients. To date, no patients have been dosed in the US AP5 study and there are no other clinical trials involving AeroLEF(TM) currently ongoing.

"We are confident that we can provide the information the FDA has requested in a timely manner," said David Allan, Chairman and CEO of YM BioSciences. "We appreciate that the FDA has to ensure that any risk to patients during clinical trials is minimized and we understand their caution with opioid-based therapeutics."

Dr. Diana Pliura, Executive Vice President, AeroLEF(TM) added, "Data reported in May 2007 from our successful randomized Phase 2b trial demonstrated that patients had a statistical and clinical benefit from AeroLEF(TM). We remain strongly committed to the clinical development of this unique product."

YM BioSciences also reported that it held its scheduled End-of-Phase 2 (EoP2) meeting with the FDA on January 16, 2007 as planned.

YM
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer

Post Your Comments:

(Date:5/16/2013)... Vernon Hills, Ill. (PRWEB) May 16, 2013 ... including benchtop and portable models, from Cole-Parmer is ... professionals. The enhanced line includes: , The new ... that are true workhorses in the lab. They ... superior serum and plasma specimen separation. Their standard ...

(Date:5/16/2013)... May 16, 2013 The registration deadline has been ... Officers (ABFO) 2013 National Conference, the premier conference for ... 28-31 at the Hilton San Diego Bayfront. ... year,s conference and want to make sure as many ... Brandi Roberts , Chief Financial Officer ...

(Date:5/16/2013)... YORK , May 16, 2013 ... new market research report is available ... Competitor Analysis: Therapeutic ... http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical ... The new ...

(Date:5/16/2013)... Dr. Stephen Y. Chou, Founder of Nanonex ... and Applications” at IEEE Nano 2013 in Beijing, China, ... by Chou, is becoming one of the most critical ... sub-10 nm resolution, large area, and low cost unmatchable ... and manufacturing in a broad range of industries, from ...

Breaking Biology Technology:Cole-Parmer Offers Enhanced Selection of Centrifuges 2 Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2 Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3 Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8 Founder, Prof. Stephen Chou to Give Tutorial on Nanoimprint at IEEE Nano 2013 2

[0] Cole-Parmer Offers Enhanced Selection of Centrifuges [0] Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego [0] Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors [0] Founder, Prof. Stephen Chou to Give Tutorial on Nanoimprint at IEEE Nano 2013

... In the news release, "Health Robotics Reports Record-Breaking Revenues,EBITDA, Net Profits, and Cash-Flow for its Fiscal Year 2009" ... the company that "EUR VAR" has been changed to "$ VAR" in,the third column header of both tables. Complete, corrected release follows: ... ... , ...

... , GREAT RIVER, N.Y. , March 15 ... enterprise-wide software and services for health and human services ... the next generation of the company,s industry leading electronic ... My Avatar software is being demonstrated at the National ...

... ... ... - Interaction of nimotuzumab with EGFRvIII, ... , , ...

/C O R R E C T I O N -- Health Robotics/Netsmart Announces 'My Avatar' at National Council for Community Behavioral Healthcare Annual Conference YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations

(Date:5/17/2013)... An international team of scientists using a new X-ray ... a living frog embryo in greater detail than ever ... biological research and the search for new treatments for ... Institut fr Technologie in Germany, in collaboration with the ... Argonne National Laboratory, released the most precise depiction ever ...

(Date:5/16/2013)... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for The Society for Developmental Biology (SDB) ... 16-20, 2013. These awards are meant to promote ... underrepresented groups into the mainstream of the basic ... young scientists at the SDB 2013 Annual Meeting. ...

(Date:5/16/2013)... shown a gene involved in neurodegenerative disease also plays ... circadian clock. , In a study of the ... Ataxin-2, keeps the clock responsible for sleeping and waking ... of the fruit fly,s sleep-wake cycle is disturbed, making ... fly. , The discovery is particularly interesting because ...

Breaking Biology News(10 mins):New X-ray method shows how frog embryos could help thwart disease 2 Gene involved in neurodegeneration keeps clock running 2

[0] New X-ray method shows how frog embryos could help thwart disease [0] MARC Travel Awards announced for the SDB 2013 72nd Annual Meeting [0] Gene involved in neurodegeneration keeps clock running

... that allergic infants may be at increased risk of peanut ... are reported in the November 1 issue of the ... Scott H. Sicherer, MD, Professor of Pediatrics, Jaffe Food Allergy ... U.S. study sites evaluated 503 infants aged three to 15 ...

... MADISON -- They are the portals to the cell, ... living cells and their environments. But these gateways -- ... outside the cell to its vital inner workings remain, ... their structures and how they work. They are of intense ...

... have shown how a protein called perforin punches holes in, ... the mechanism of this assassin is published today in the ... of cleansing and death," says project leader Prof James Whisstock ... been hijacked by viruses or turned into cancer cells and ...

Cached Biology News:Pregnant women who eat peanuts may put infants at increased risk for peanut allergy 2 Chemists concoct new agents to easily study critical cell proteins 2 How do we kill rogue cells? 2

Pregnant women who eat peanuts may put infants at increased risk for peanut allergy Chemists concoct new agents to easily study critical cell proteins How do we kill rogue cells?

Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...

Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...

HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....

Human CXCL14/BRAK Affinity Purified Polyclonal Ab...

Biology Products:

Goat Anti-Human RELT / TNFRSF19L Polyclonal Antibody, Unconjugated from R&D Systems Goat Anti-Mouse NOV / CCN3 Polyclonal Antibody, Unconjugated from R&D Systems HiTrap NHS-activated HP from GE Healthcare, formerly Amersham Biosciences Goat Anti-Human CXCL14 / BRAK Polyclonal Antibody, Unconjugated from R&D Systems